Association of out-of-pocket pharmacy costs with adherence to varenicline.
Suehs, Brandon T; Davis, Cralen; Galaznik, Aaron; Joshi, Ashish V; Zou, Kelly H; Patel, Nick C.
J Manag Care Spec Pharm
; 20(6): 592-600, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24856597
Budgetary impact of varenicline in smoking cessation in the United Kingdom.
Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.
A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION).
Funding a smoking cessation program for Crohn's disease: an economic evaluation.
Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
Varenicline: a first-line treatment option for smoking cessation.
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation.